Ranolazine is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).
For this indication, competent medicine agencies globally authorize below treatments:
750 - 1,500 mg
From 375 To 750 mg 2 time(s) per day every day
The recommended initial dose of ranolazine is 375 mg twice daily. After 2–4 weeks, the dose should be titrated to 500 mg twice daily and, according to the patient’s response, further titrated to a recommended maximum dose of 750 mg twice daily.
If a patient experiences treatment-related adverse events (e.g. dizziness, nausea, or vomiting), downtitration of ranolazine to 500 mg or 375 mg twice daily may be required. If symptoms do not resolve after dose reduction, treatment should be discontinued.
The incidence of adverse events was higher in patients with low weight (≤60 kg). Dose titration in patients with low weight should be exercised with caution.
Dose titration in elderly patients should be exercised with caution. Elderly may have increased ranolazine exposure due to age-related decrease in renal function. The incidence of adverse events was higher in the elderly.
They may be taken with or without food.